Seeking Alpha


Send Message
View as an RSS Feed
View Rymet's Comments BY TICKER:
Latest  |  Highest rated
  • Formation Of A New Expert Group Moves Pluristem Into The Expansive Hematology Field [View article]
    Next rewards in regenerative medicine, Athersys, Inc. and Neostem, Inc.

    Athersys (ATHX) has a moderate risk, but it also carries with it a high reward. With only 50M shares in the float, even a $5 stock price would only give Athersys a $250M market cap for a company pursuing at least 8 market opportunities with each of them worth billions that's nothing. A big positive for Athersys is Big Pharma’s support in its therapy development efforts, which showcases the high commercial potential of the therapy. The company has forged a partnership with Pfizer for developing the MultiStem treatment for inflammatory bowel disease (IBD). RTI Biologics, a small but leading developer, has partnered to help develop MultiStem for use in orthopedic treatment along with a bone allograft. Considering the promise shown by MultiStem in treating multiple disorders, it is very likely that other big pharmaceutical companies engaged in treatment of inflammatory and related diseases will come forward and partner Athersys for finding new uses.
    Advantage over competitors MultiStem, which is developed from human bone marrow cells, is being tested for treatment of a large number of diseases. Both Osiris and Cytori do not have such a base technology ready to implement in developing their products
    for large number ailments. Also, MultiStem can be used to culture millions of off-the-shelf doses from one donor, whereas Osiris can produce about 10 times less than those with mesenchymal stem cells (the cell type it uses to develop its products).
    As for Neostem (NBS) it's for real:

    The U.S. National Institutes of Health believes in it NBS for a reason. NeoStem, has been invited to present at an industry conference next week on the topic of AMR-001, the Company's lead product candidate Neostem just began to trade on the NASDAQ in August 2013 and has a relatively small float and an eye opening pipeline.
    Aug 15 12:52 PM | Likes Like |Link to Comment
  • Osiris - An Impressive Short Squeeze Leads To A Potential Shorting Opportunity [View article]
    Good luck... not sure you will be getting your 10%... At least you are at profit today. :-)
    Aug 15 11:56 AM | Likes Like |Link to Comment
  • Osiris - An Impressive Short Squeeze Leads To A Potential Shorting Opportunity [View article]
    Amit Ghate, Shorting a stock that will clearly head higher in the not so distant future and then trying to advise others to do the same is ridiculous. Where was the call to short at $27.40

    Buy to cover and go long.
    Aug 15 11:34 AM | 2 Likes Like |Link to Comment
  • Athersys: Extreme Undervaluation Poses An Opportunity [View article]
    I agree scan of all the potential "next OSIR type stocks" reveals ATHX to be the best choice... number two would be PSTI.

    It's a rather big list... you did your homework well Josh :-)
    Aug 14 05:45 PM | 1 Like Like |Link to Comment
  • Korean Partner Positions Pluristem To Be Cell Therapy Leader [View article]
    Curious as to why you have chosen PSTI over ATHX? American companies generally fare better than companies in Israel in terms of share price. Technology in Israel is first rate however investing in a small country surrounded by hostile neighbors scares most investors away. For this reason ATHX makes a more sound choice for stocks in the same field. Correct me if I am missing some major difference here?
    Aug 14 03:59 PM | 1 Like Like |Link to Comment
  • Oramed: An Early-Stage Biotech Company With Huge Potential [View article]
    I will take a pass on ORMP in favor of drugs in the same field as Osiris Therapeutics, Inc.(OSIR) that has risen from the $10 area yesterday to a high of the day today of $27.40... even higher pre-market.

    One such company is ATHX with even greater potential than OSIR.

    As far as ORMP is really any better than MNKD... ? GNBT has Oral-lyn and it's done very little to help GNBT's bottom line.
    Aug 14 03:58 PM | Likes Like |Link to Comment